Creabilis Announces Headline Results Of Its Phase 2b Trial Of Topical TrkA Kinase Inhibitor CT327

Clinically and Statistically Significant Reduction of Chronic Pruritus (Itch) Seen in Psoriasis Patients Creabilis, a late stage European dermatology company with a focus on chronic pruritus (itch), has announced headline results of its Phase 2b trial with its lead product, CT327, in psoriasis patients. CT327 is a novel, topical, TrkA kinase inhibitor developed using Creabilis' LSE (Low Systemic Exposure) technology that creates 'topical-by-design' drugs...
Source: Health News from Medical News Today - Category: Consumer Health News Tags: Eczema / Psoriasis Source Type: news